Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Maggio, Ignazio ^a   Holkers, Maarten ^a   Liu, Jin ^a   Janssen, Josephine M ^a   Chen, Xiaoyu ^a   Gonçalves, Manuel A F V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GUIDE RNA;

ADENOVIRIDAE; CRISPR CAS SYSTEM; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; MUTAGENESIS;

ADENOVIRIDAE; CRISPR-CAS SYSTEMS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MUTAGENESIS; RNA, GUIDE;

EID: 84901711327     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05105     Document Type: Article

References (43)

1. Gaj, T., Gersbach, C.A. & Barbas, C.F. 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397-405 (2013).
2. Segal, D. J. & Meckler, J. F. Genome engineering at the dawn of the golden age. Annu. Rev. Genomics Hum. Genet. 14, 135-158 (2013).
3. Biasco, L., Baricordi, C. & Aiuti, A. Retroviral integrations in gene therapy trials. Mol. Ther. 20, 709-716 (2012).
4. Bhaya, D., Davison, M. & Barrangou, R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu. Rev. Genet. 45, 273-297 (2011).
5. Wiedenheft, B., Sternberg, S. H. & Doudna, J. A. RNA-guided genetic silencing systems in bacteria and archaea. Nature 482, 331-338 (2012).
6. Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl. Acad. Sci. USA 109, E2579-E2586 (2012).
7. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).
8. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
9. Jinek, M. et al. RNA-programmed genome editing in human cells. Elife 2, e00471 (2013).
10. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013).
11. Gasiunas, G. & Siksnys, V. RNA-dependent DNA endonuclease Cas9 of the CRISPR system: Holy Grail of genome editing? Trends Microbiol. 21, 562-567 (2013).
12. Cradick, T. J., Fine, E. J., Antico, C. J. & Bao, G. CRISPR/Cas9 systems targeting b-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 41, 9584-9592 (2013).
13. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822-826 (2013).
14. Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827-832 (2013).
15. Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833-838 (2013).
16. Pattanayak, V. et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol. 31, 839-843 (2013).
17. Gonçalves, M. A. F. V. & de Vries, A. A. F. Adenovirus: from foe to friend. Rev Med. Virol. 16, 167-186 (2006). (Pubitemid 43864965)
18. Holkers, M. et al. Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. Nucleic Acids Res. 41, e63 (2013).
19. Shayakhmetov, D. M., Papayannopoulou, T., Stamatoyannopoulos, G. & Lieber, A. Efficient gene transfer into human CD34(1) cells by a retargeted adenovirus vector. J. Virol. 74, 2567-2583 (2000). (Pubitemid 30117566)
20. Knaän-Shanzer, S. et al. Highly efficient targeted transduction of undifferentiated human hematopoietic cells by adenoviral vectors displaying fiber knobs of subgroup B. Hum. Gene Ther. 12, 1989-2005 (2001). (Pubitemid 33116765)
21. Erratum in: Hum. Gene Ther. 14, 1214 (2003).
22. Knaän-Shanzer, S. et al. Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. Stem Cells 23, 1598-1607 (2005). (Pubitemid 41741009)
23. Gonçalves, M. A. F. V. et al. Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells. Mol. Ther. 13, 976-986 (2006).
24. Gonçalves, M. A. F. V., van der Velde, I., Knaän-Shanzer, S., Valerio, D. & de Vries, A. A. F. Stable transduction of large DNA by high-capacity adeno-associated virus/adenovirus hybrid vectors. Virology 321, 287-296 (2004). (Pubitemid 38406042)
25. Barouch, D. H. & Nabel, G. J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum. Gene Ther. 16, 149-156 (2005). (Pubitemid 40344207)
26. Post, D. E., Khuri, F. R., Simons, J. W. & van Meir, E. G. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum. Gene Ther. 14, 933-946 (2003). (Pubitemid 36829727)
27. Aurisicchio, L. & Ciliberto, G. Genetic cancer vaccines: current status and perspectives. Expert. Opin. Biol. Ther. 12, 1043-1058 (2012).
28. Perez, E. E. et al. Establishment of HIV-1 resistance in CD41 T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26, 808-816 (2008). (Pubitemid 351961450)
29. Ebina, H., Misawa, N., Kanemura, Y. & Koyanagi, Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci. Rep. 3, 2510 (2013).
30. Kim, H. et al. Surrogate reporters for enrichment of cells with nuclease-induced mutations. Nat. Methods 8, 941-943 (2011).
31. Pelascini, L. P. et al. Histone deacetylase inhibition rescues gene knockout levels achieved with integrase-defective lentiviral vectors encoding zinc-finger nucleases. Hum. Gene Ther. Methods 24, 399-411 (2013).
32. Pelascini, L. P., Janssen, J. M. & Gonçalves, M. A. F. V. Histone deacetylase inhibition activates transgene expression from integration-defective lentiviral vectors in dividing and non-dividing cells. Hum. Gene Ther. 24, 78-96 (2013).
33. Ferrari, F. K., Samulski, T., Shenk, T. & Samulski, R. J. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70, 3227-3234 (1996). (Pubitemid 26121941)
34. Ding, Q. et al. Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 12, 393-394 (2013).
35. Havenga, M. J. et al. Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity. Biotechnol. Bioeng. 100, 273-283 (2008). (Pubitemid 351758170)
36. Cudré-Mauroux, C. et al. Lentivector-mediated transfer of Bmi-1 and telomerase in muscle satellite cells yields a duchenne myoblast cell line with long-term genotypic and phenotypic stability. Hum. Gene Ther. 14, 1525-1533 (2003). (Pubitemid 37357740)
37. Gonçalves, M. A. F. V. et al. Transcription factor rational design improves directed differentiation of human mesenchymal stem cells into skeletal myocytes. Mol. Ther. 19, 1331-1341 (2011).
38. Fallaux, F. J. et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909-1917 (1998). (Pubitemid 28439096)
39. rd Ed. Sambrook, J. F. & Russell, D. W. (eds.) (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001).
40. Holkers, M., Cathomen, T. & Gonçalves, M. A. F. V. Construction and characterization of adenoviral vectors for the delivery of TALENs into human cells. Methods S1046-2023 (2014). Epub ahead of print. doi:10.1016/j.ymeth.2014.02.017.
41. Coluccio, A. et al. Targeted gene addition in human epithelial stem cells by zinc-finger nuclease-mediated homologous recombination. Mol. Ther. 21, 1695-1704 (2013).
42. Janssen, J. M., Liu, J., Skokan, J., Gonçalves, M. A. F. V. & de Vries, A. A. F. Development of an AdEasy-based system toproduce first-and second-generation adenoviral vectors with tropism for CAR-or CD46-positive cells. J. Gene Med. 15, 1-11 (2013).
43. Laird, P. W. et al. Simplified mammalian DNA isolation procedure. Nucleic Acids Res. 19, 4293 (1991).